Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Xiaoyan Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3193-1401; OpenAlex author ID A5100352069. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers

Papers 4

  1. NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.1093/carcin/bgac102↗
  2. Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV… Co-author DOI 10.1158/2767-9764.crc-23-0137↗
  3. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. First author DOI 10.1038/s41392-020-00260-1↗
  4. Dietary Patterns and Pancreatic Cancer Risk: A Meta-Analysis. Last author DOI 10.3390/nu9010038↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Wang · 1 shared paper, 2023 · strength 0.17
  2. Wei Zhang · 1 shared paper, 2023 · strength 0.17
  3. Jianqing Xu · 1 shared paper, 2023 · strength 0.17
  4. Yan Ma · 1 shared paper, 2023 · strength 0.15
  5. Xiaomeng He · 1 shared paper, 2023 · strength 0.15
  6. Shanshan Liu · 1 shared paper, 2023 · strength 0.15
  7. Jin Wang · 1 shared paper, 2023 · strength 0.15
  8. Mao Lin · 1 shared paper, 2020 · strength 0.11
  9. Jibing Chen · 1 shared paper, 2020 · strength 0.11
  10. Mohammed Alnaggar · 1 shared paper, 2020 · strength 0.11
  11. Yong Jiang · 1 shared paper, 2020 · strength 0.11
  12. Lizhi Niu · 1 shared paper, 2020 · strength 0.11
  13. Peiying Lu · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.